8-K: Amphastar Pharmaceuticals Stockholders Approve Key Governance Changes and Elect Directors at Annual Meeting

Amphastar Pharmaceuticals, Inc. announced that its stockholders approved significant amendments to its corporate charter and bylaws, including officer exculpation and revised forum selection provisions, alongside the election of three Class III directors and ratification of its independent auditor.

Summary

• At the 2025 Annual Meeting of Stockholders held on June 2, 2025, Amphastar Pharmaceuticals, Inc. stockholders voted on and approved several key proposals.
• Stockholders approved amendments to the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions regarding officer exculpation and to remove a previous forum selection provision.
• In connection with the removal of the charter's forum selection provision, the Board of Directors approved an amendment to the Company's bylaws, clarifying that Delaware courts will be the sole and exclusive forum for certain internal corporate claims, and U.S. federal district courts for Securities Act claims.
• Three Class III directors, Jack Y. Zhang, Richard Prins, and Diane G. Gerst, were duly elected to serve until the Company's 2028 annual meeting of stockholders.
• The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified by stockholders.
• Stockholders also approved, on an advisory basis, the compensation of the Company's named executive officers.

Sentiment

Score: 7

Explanation: The document reports on the successful approval of all corporate governance proposals and director elections at the annual meeting, indicating a stable and well-supported governance framework. No negative or unexpected outcomes were reported.

Positives

• All proposed amendments to the Charter and Bylaws were approved by stockholders, indicating strong support for the Company's governance initiatives.
• The election of three Class III directors ensures continuity and stability in the Board of Directors until the 2028 annual meeting.
• The ratification of Ernst & Young LLP as the independent auditor for fiscal year 2025 demonstrates ongoing confidence in the Company's financial oversight.
• The advisory approval of named executive officer compensation suggests stockholder alignment with the Company's executive remuneration practices.

Risks

• The Exculpation Amendment limits the personal monetary liability of officers for certain breaches of fiduciary duty, potentially shifting some risk from individual officers to the Company and its stockholders.
• The new forum selection provision in the Bylaws, while common, centralizes certain types of litigation to Delaware courts and U.S. federal district courts for Securities Act claims, which could impact the venue and associated costs for stockholders seeking to bring certain actions.

Future Outlook

The document does not provide specific forward-looking statements or financial guidance, focusing solely on the outcomes of the annual stockholder meeting and corporate governance updates.

Industry Context

The corporate governance changes, including officer exculpation and forum selection provisions, are common practices among Delaware-incorporated public companies, reflecting efforts to align with current legal standards and streamline potential litigation venues. The election of directors and ratification of auditors are routine annual meeting agenda items for publicly traded companies.

Comparison to Industry Standards

• The adoption of officer exculpation provisions aligns with recent amendments to Delaware General Corporation Law (DGCL) allowing for the limitation of officer liability, a trend many Delaware-incorporated companies are following.
• The implementation of exclusive forum provisions for internal corporate claims in Delaware courts and for Securities Act claims in U.S. federal district courts is a widely adopted practice among public companies to manage litigation risk and avoid multi-forum litigation.

Corporate Governance

Legal Proceedings

• The document details amendments to the Company's charter and bylaws regarding forum selection for future legal proceedings, specifically derivative actions, breach of fiduciary duty claims, actions under DGCL, internal affairs doctrine claims, and Securities Act of 1933 claims. No current legal proceedings are disclosed.

Stakeholder Impact

• **Shareholders**: The officer exculpation amendment may shift some liability risk from officers to the Company and its shareholders. The forum selection amendments aim to centralize litigation, potentially affecting the venue and costs for shareholders bringing certain types of claims.
• **Officers**: The officer exculpation amendment provides increased protection against personal monetary liability for certain breaches of fiduciary duty, aligning with recent changes in Delaware law.

Next Steps

• The newly elected Class III directors will serve until the 2028 annual meeting of stockholders.
• Ernst & Young LLP will continue as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

SEC filing, corporate governance, bylaws amendment, charter amendment, stockholder meeting, officer exculpation, forum selection, director election, auditor ratification, executive compensation, Amphastar Pharmaceuticals